EL
ELDN.US Eledon Pharmaceuticals Inc
- Market cap
- USD 172M
- P/E
- -
- P/B
- 5.83x
- ROE
- -142.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ELDN.US undervalued?
Graham numberThe Graham number of Eledon Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eledon Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Eledon Pharmaceuticals Inc yet.
Eledon Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developin…
Full company profileEledon Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eledon Pharmaceuticals Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 120K | 120K | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -35.0K | -22.0K | -11.0K | -182K | -183K | 120K | -373K | -374K | -359K | - | - |
| Operating Income | -38.1M | -13.1M | -14.1M | -14.2M | -18.5M | -36.9M | -88.4M | -43.0M | -70.6M | -83.3M | -87.6M |
| EBITDA | -6.90M | -13.1M | -14.0M | -15.8M | -16.0M | -36.7M | -39.4M | -42.6M | -35.4M | -45.3M | -76.1M |
| Net Income | -38.0M | -13.1M | -14.1M | -16.0M | -22.8M | -34.5M | -88.0M | -40.3M | -36.2M | -45.6M | -99.5M |
| EPS | -9.14 | -2.80 | -1.56 | -1.36 | -1.50 | -2.33 | -6.16 | -1.64 | -0.75 | -0.56 | -0.87 |
| Balance Sheet | |||||||||||
| Total Assets | 29.8M | 20.9M | 17.0M | 10.9M | 197M | 171M | 92.8M | 126M | 177M | 169M | 107M |
| Total Liabilities | 2.90M | 1.44M | 2.53M | 1.47M | 6.59M | 6.55M | 8.61M | 42.5M | 59.3M | 87.9M | 36.8M |
| Shareholders' Equity | 26.9M | 19.5M | 14.5M | 9.47M | 191M | 164M | 84.2M | 83.4M | 118M | 81.1M | 69.8M |
| Cash & Short-term Investments | 27.4M | 17.2M | 13.0M | 8.79M | 114M | 84.8M | 56.4M | 51.1M | 140M | 133M | 69.7M |
| Total Debt | 3.45M | - | - | 324K | 144K | 769K | 746K | 383K | 954K | 641K | 376K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -36.5M | -14.9M | -11.9M | -13.9M | -15.2M | -28.9M | -28.4M | -39.5M | -47.3M | -62.3M | -85.7M |
| Capital Expenditure | 17.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -36.5M | -14.9M | -11.9M | -13.9M | -15.2M | -28.9M | -28.4M | -39.5M | -47.3M | -62.3M | -85.7M |
| Ratios | |||||||||||
| ROE | -141.3% | -67.4% | -97.1% | -169.2% | -12.0% | -21.0% | -104.5% | -48.3% | -30.6% | -56.3% | -142.5% |
| ROA | -127.5% | -62.8% | -82.6% | -146.5% | -11.6% | -20.2% | -94.8% | -32.0% | -20.4% | -27.0% | -93.3% |
| Net Profit Margin | - | - | - | - | -19,009.2% | -28,755.0% | - | - | - | - | - |
| Debt to Equity | 0.13x | - | - | 0.03x | 0.00x | 0.00x | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eledon Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 25.0K | 0.00 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:18 on Oct 5, 2020.
Who owns Eledon Pharmaceuticals Inc
- Insiders 0.90%
- Institutions 56.86%
- Public & others 42.24%
- Shares outstanding 81.3M
- Free float 77.5M
Top funds holding ELDN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.48M | 3.06% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.99M | 2.45% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 839K | 1.03% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 732K | 0.90% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 450K | 0.55% | +1.82% | Sep 2026 |
| Fidelity Extended Market Index | 383K | 0.47% | +4.52% | Sep 2026 |
| Goldman Sachs Small Cap Eq Insghts Instl | 312K | 0.38% | +74.44% | Jul 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 286K | 0.35% | -12.82% | Jul 2026 |
| GS US Sm Cp CORE Eq Base Inc USD Snap | 281K | 0.35% | +1.10% | Aug 2026 |
| iShares Micro-Cap ETF | 231K | 0.28% | 0.00% | Oct 2026 |
| Dimensional US Small Cap ETF | 197K | 0.24% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 187K | 0.23% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 164K | 0.20% | -6.50% | Sep 2026 |
| Fidelity Total Market Index | 141K | 0.17% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 135K | 0.17% | 0.00% | Sep 2026 |
| Goldman Sachs Small Cap Gr Insghts Instl | 130K | 0.16% | +151.40% | Jul 2026 |
| Fidelity Series Total Market Index | 119K | 0.15% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 112K | 0.14% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 106K | 0.13% | +219.84% | Oct 2026 |
Top institutions holding ELDN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Bvf Inc | 6.29M | 7.74% | 0.00% | Jun 2026 |
| BlackRock Inc | 5.12M | 6.31% | +16.92% | Jun 2026 |
| Defilade Capital Management, L.P. | 3.53M | 4.34% | -1.09% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.42M | 4.21% | +3.77% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.51M | 3.09% | +578.30% | Jun 2026 |
| Ensign Peak Advisors Inc | 2.10M | 2.59% | -14.75% | Jun 2026 |
| Geode Capital Management, LLC | 1.96M | 2.41% | +9.20% | Jun 2026 |
| Catalio Capital Management, LP | 1.70M | 2.09% | +3.37% | Jun 2026 |
| State Street Corp | 1.62M | 2.00% | +40.47% | Jun 2026 |
| Zimmer Partners LP | 1.60M | 1.96% | -14.85% | Jun 2026 |
| Sphera Funds Management Ltd. | 1.19M | 1.47% | -32.78% | Jun 2026 |
| Awm Investment Company Inc | 1.10M | 1.35% | 0.00% | Jun 2026 |
| UBS Group AG | 1.05M | 1.29% | +91.48% | Jun 2026 |
| Kingdon Capital Management LLC | 1.04M | 1.28% | 0.00% | Jun 2026 |
| Millennium Management LLC | 980K | 1.21% | 0.00% | Jun 2026 |
| Bank of America Corp | 883K | 1.09% | +1.56% | Jun 2026 |
| ADAR1 Capital Management LLC | 648K | 0.80% | -33.52% | Jun 2026 |
| 22NW, LP | 636K | 0.78% | 0.00% | Jun 2026 |
| Northern Trust Corp | 616K | 0.76% | +13.34% | Jun 2026 |
| AQR Capital Management LLC | 581K | 0.72% | +236.99% | Jun 2026 |
Eledon Pharmaceuticals Inc company profile
- Company name
- Eledon Pharmaceuticals Inc
- Ticker
- ELDN.US
- Exchange
- USA Stocks
- Listed since
- Sep 17, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 19800 MacArthur Boulevard, Irvine, CA, United States, 92612
- Phone
- 949 238 8090
- Website
- eledon.com
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Eledon Pharmaceuticals Inc management
8- Dr. David-Alexandre C. Gros M.D., Ph.D.CEO & Non Independent Director · born 1972
- Dr. Steven N. Perrin Ph.D.President, Chief Scientific Officer & Non Independent Director · born 1966
- Mr. Paul Sean LittleChief Financial Officer · born 1965
- Mr. John HerbergerVice President of Technical Operations
- Mr. Bryan E. Smith J.D.General Counsel, Corporate Secretary & Chief Compliance Officer · born 1980
- Dr. David Hovland Ph.D.Chief Regulatory Officer
- Ms. Marina EscuderoVP & Head of Clinical Operations
- Dr. Sepideh HabibiVP and Head of Safety & Pharmacovigilance